Samarth Kulkarni Crispr Therapeutics Ag (CRSP) insider trading activity

Samarth Kulkarni is Chief Executive Officer of CRISPR Therapeutics AG. Currently has a direct ownership of 195,085 shares of CRSP, which is worth approximately $7.37 Million. The most recent transaction as insider was on Apr 24, 2017, when has been sold 3,500 shares (Common Shares) at a price of $1.81 per share, resulting in proceeds of $6,335. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 195K

0.11% 3M change

6.26% 12M change

Total Value Held $7.37 Million

Samarth Kulkarni Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Apr 24 2017	BUY Exercise of conversion of derivative security	$6,335 $1.81 p/Share	3,500 Added 2.48%	137,547 Common Shares
Apr 21 2017	SELL Open market or private sale	$51,030 $17.01 p/Share	3,000 Reduced 2.19%	134,047 Common Shares
Apr 21 2017	BUY Exercise of conversion of derivative security	$5,430 $1.81 p/Share	3,000 Added 2.14%	137,047 Common Shares
Apr 20 2017	SELL Open market or private sale	$48,608 $17.36 p/Share	2,800 Reduced 2.05%	134,047 Common Shares
Apr 20 2017	BUY Exercise of conversion of derivative security	$5,068 $1.81 p/Share	2,800 Added 2.01%	136,847 Common Shares
Apr 19 2017	SELL Open market or private sale	$130,934 $18.04 p/Share	7,258 Reduced 5.14%	134,047 Common Shares
Apr 19 2017	BUY Exercise of conversion of derivative security	$13,137 $1.81 p/Share	7,258 Added 4.89%	141,305 Common Shares

Also insider at

BDTX

Black Diamond Therapeutics, Inc. Healthcare

RPTX

Repare Therapeutics Inc. Healthcare

CNTA

Centessa Pharmaceuticals plc Healthcare

Director